Modulation of the humoral and cellular immune response in Abeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G). (Q54481541)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Modulation of the humoral and cellular immune response in Abeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G).	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/16054274

Modulation of the humoral and cellular immune response in Abeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G). (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/16054274

Escherichia coli

0 references

0 references

1 reference

based on heuristic

inferred from title

author name string

Marcel Maier

1

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/16054274

Timothy J Seabrook

2

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/16054274

Cynthia A Lemere

3

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/16054274

language of work or name

0 references

publication date

1 October 2005

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/16054274

number of pages

11

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/16054274

23

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/16054274

44

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/16054274

5149-5159

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/16054274

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Strategies for disease modification in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Nerve inflammation halts trial for Alzheimer's drug.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Evaluation of the safety and immunogenicity of synthetic A 42 (AN1792) in patients with AD

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Set back to Alzheimer vaccine studies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Effect of monophosphoryl lipid A (MPL) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM197 conjugate vaccine in healthy toddlers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Cancer vaccines entering Phase III clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Immunostimulatory activity of aminoalkyl glucosaminide 4-phosphates (AGPs): induction of protective innate immune responses by RC-524 and RC-529.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Monophosphoryl lipid A activates both human dendritic cells and T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Effective adjuvants for the induction of antigen-specific delayed-type hypersensitivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Immunological properties of trehalose dimycolate (cord factor) and other mycolic acid-containing glycolipids--a review

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Cholera toxin and related enterotoxins as potent immune modulators

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

A comparison of natural and recombinant cholera toxin B subunit as stimulatory factors in intranasal immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Mucosal and systemic antibody responses after peroral or intranasal immunization: effects of conjugation to enterotoxin B subunits and/or of co-administration with free toxin as adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Species-specific immune response to immunization with human versus rodent A beta peptide.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Differences in the immune response to long term Abeta vaccination in C57BL/6 and B6D2F1 mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Cholera toxin activates dendritic cells through dependence on GM1-ganglioside which is mediated by NF-kappaB translocation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Lymphokine control of in vivo immunoglobulin isotype selection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated beta-amyloid 1-42 peptide.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Concordance and contradiction concerning cytokines and chemokines in experimental demyelinating disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Experimental autoimmune encephalomyelitis in the rat: lessons in T-cell immunology and autoreactivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's beta-amyloid(1-42).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Immune responses against Abeta1-42 in HLA class II transgenic mice: implications for Abeta1-42 immune-mediated therapies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Effects of intranasal administration of cholera toxin (or Escherichia coli heat-labile enterotoxin) B subunits supplemented with a trace amount of the holotoxin on the brain.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

The CTA1-DD vaccine adjuvant binds to human B cells and potentiates their T cell stimulating ability

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.018

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2005.06.018

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/16054274

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/16054274

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54481541&oldid=1775334842"